RIGL — Rigel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $882.62m
- $826.53m
- $294.28m
Brief: Rigel Announces First Patient Enrolled In Dose Expansion Phase Of 1B Study Of R289 In Patients With Lower-Risk MDS
Brief: Rigel Pharmaceuticals Announces Inducement Grants
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue beats estimates
Rigel Pharmaceuticals Inc expected to post earnings of $2.58 a share - Earnings Preview
Rigel Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Rigel Pharmaceuticals Q1 EPS USD 0.64 Vs. IBES Estimate USD 0.02
Rigel Pharmaceuticals Inc expected to post earnings of 2 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ultragenyx Pharma, Winnebago, Par Pacific
U.S. STOCKS ON THE MOVE-Rigel Pharma, Concentrix, Avis Budget
Rigel climbs on blood disorder drug patent settlement
Brief: Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation
Brief: Rigel appoints Mark W. Frohlich to its board
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Rigel Pharmaceuticals Inc expected to post earnings of 47 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Amneal pharma, Aramark, Bluebird Bio
U.S. RESEARCH ROUNDUP-Jll, Mongodb, Rigel Pharmaceuticals
Brief: Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary